Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17B | O94768 | 6/20 | 0.55 |
| ▸ | PNLIP | P16233 | 4/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | AURKA | O14965 | 2/20 | 0.46 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.46 |
| ▸ | GSK3B | P49841 | 2/20 | 0.46 |
| ▸ | BLK | P51451 | 2/20 | 0.46 |
| ▸ | BTK | Q06187 | 2/20 | 0.46 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.46 |
| ▸ | DAPK2 | Q9UIK4 | 2/20 | 0.46 |
| ▸ | IKBKB | O14920 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.44 |
| ▸ | TEK | Q02763 | 1/20 | 0.44 |
| ▸ | ITK | Q08881 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3051171 | 0.94 | STK17B (0.52) | STK17BPNLIPMAOBAURKADAPK3 | |
| SCHEMBL3038639 | 0.94 | STK17B (0.52) | STK17BPNLIPMAOBAURKADAPK3 | |
| SCHEMBL3045002 | 0.78 | STK17B (0.59) | STK17BPNLIPMAOBAURKADAPK3 | |
| SCHEMBL3045006 | 0.78 | STK17B (0.59) | STK17BPNLIPMAOBAURKADAPK3 | |
| SCHEMBL3042357 | 0.73 | STK17B (0.55) | STK17BPNLIPMAOBAURKADAPK3 | |
| SCHEMBL3046717 | 0.73 | STK17B (0.55) | STK17BPNLIPMAOBAURKADAPK3 | |
| SCHEMBL3046715 | 0.73 | STK17B (0.55) | STK17BPNLIPMAOBAURKADAPK3 | |
| SCHEMBL14861961 | 0.69 | STK17B (0.50) | STK17BPNLIPMAOB | |
| SCHEMBL6611267 | 0.68 | APP (0.60) | — | |
| SCHEMBL6807830 | 0.68 | APP (0.60) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100003191-A1 | AURONE DERIVATIVE-CONTAINING COMPOSITION FOR DIAGNOSIS | NAGASAKI UNIVERSITY (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2113258-A1 | AURONE DERIVATIVE-CONTAINING COMPOSITION FOR DIAGNOSIS | Nagasaki University (JP) | 2009-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003191-A1 | AURONE DERIVATIVE-CONTAINING COMPOSITION FOR DIAGNOSIS | APP, APBA1, BACE1 | STK17B 772/4885PNLIP 4797/4885MAOB 1034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.